ClinicalTrials.gg
CompletedNCT00487747Updated Apr 6, 2017Results posted

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 23 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
56th of 59
18 · median 114
Started
2006
with 4 others
Phase 4
29 of 59
none open now
Registered
10th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 56th largest by enrollment, is one of 5 that started in 2006, is one of 29 in phase 4, and was the 10th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis B who are either treatment-naive, or who have failed lamivudine- or interferon-treatment in the past. All patients will receive PEGASYS, 180 micrograms s.c. weekly for 48 weeks, followed by 48 weeks of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-70 years of age;
  • chronic ;
  • Hepatitis B Virus (HBV) DNA >100,000 copies/mL.

Exclusion criteria

Exclusion Criteria:

  • previous antiviral or interferon-based therapy for chronic in past 6 months;
  • evidence of decompensated liver disease;
  • history or evidence of a medical condition associated with chronic liver disease other than viral hepatitis;
  • coinfection with hepatitis A, C or D, or .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Peginterferon Alfa-2a

    Drug: peginterferon alfa-2a [Pegasys]

Interventions

06

What researchers measure

Primary outcomes

  1. Number of HBeAg Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid <100,000 Copies Per mL

    This study included four Hepatitis B Early Antigen (HBeAg) positive participants. Participants with Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) \<100,000 copies/mL were reported.

    Time frame: Week 96

  2. Number of HBeAg Negative Participants With HBV DNA < 20,000 Copies Per mL

    This study included 14 HBeAg negative participants. Participants with HBV DNA \<20,000 copies/mL were reported.

    Time frame: Week 96

Secondary outcomes

  1. Number of HBeAg Positive Participants With HBV DNA <400 Copies Per mL, HBsAg Seroconversion, Normalization of ALT, and Sustained HBe Seroconversion

    Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of Hepatitis B surface antibody (HBsAb). Sustained HBe seroconversion is defined as loss of HBeAg and presence of hepatitis B e-antibody (HBeAb). This study included 4 HBeAg positive participants.

    Time frame: Week 96

  2. Number of HBeAg Negative Participants With HBV DNA <400 Copies/mL, HbsAg Seroconversion and Normalization of ALT

    Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of HBsAb. This study included 14 HBeAg negative participants.

    Time frame: Week 96

  3. Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)

    All participants who received at least one dose of the study drug were analysed. Number of participants with any adverse events and any serious adverse events are reported.

    Time frame: Up to Week 96

  4. Mean Change in Laboratory Parameters (ALT Levels)

    Mean Change in Laboratory parameters (ALT levels) is reported.

    Time frame: From Screening (Day 0) to Week 96

07

Results

Posted Apr 6, 2017

Participant flow

The study was conducted at 7 centers in Russia.

Participant flow — Overall Study
MilestonePeginterferon Alfa-2a
Started18
Completed7
Not completed11
Withdrew: Adverse event1
Withdrew: Lost to follow-up9
Withdrew: Lack of efficacy1

Outcome measures

PrimaryNumber of HBeAg Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid <100,000 Copies Per mL

This study included four Hepatitis B Early Antigen (HBeAg) positive participants. Participants with Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) \<100,000 copies/mL were reported.

Time frame:
Week 96
Reported as:
Number · Participants
Number of HBeAg Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid <100,000 Copies Per mL
ParticipantsPeginterferon Alfa-2a
Number of HBeAg Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid <100,000 Copies Per mL4
PrimaryNumber of HBeAg Negative Participants With HBV DNA < 20,000 Copies Per mL

This study included 14 HBeAg negative participants. Participants with HBV DNA \<20,000 copies/mL were reported.

Time frame:
Week 96
Reported as:
Number · Participants
Number of HBeAg Negative Participants With HBV DNA < 20,000 Copies Per mL
ParticipantsPeginterferon Alfa-2a
Number of HBeAg Negative Participants With HBV DNA < 20,000 Copies Per mL3
SecondaryNumber of HBeAg Positive Participants With HBV DNA <400 Copies Per mL, HBsAg Seroconversion, Normalization of ALT, and Sustained HBe Seroconversion

Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of Hepatitis B surface antibody (HBsAb). Sustained HBe seroconversion is defined as loss of HBeAg and presence of hepatitis B e-antibody (HBeAb). This study included 4 HBeAg positive participants.

Time frame:
Week 96
Reported as:
Number · Participants
Number of HBeAg Positive Participants With HBV DNA <400 Copies Per mL, HBsAg Seroconversion, Normalization of ALT, and Sustained HBe Seroconversion
ParticipantsPeginterferon Alfa-2a
HBV DNA <400 copies/mL4
HBsAg seroconversion0
ALT normalization4
Sustained HBe seroconversion4
SecondaryNumber of HBeAg Negative Participants With HBV DNA <400 Copies/mL, HbsAg Seroconversion and Normalization of ALT

Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of HBsAb. This study included 14 HBeAg negative participants.

Time frame:
Week 96
Reported as:
Number · Participants
Number of HBeAg Negative Participants With HBV DNA <400 Copies/mL, HbsAg Seroconversion and Normalization of ALT
ParticipantsPeginterferon Alfa-2a
HBV DNA <400 copies/mL3
HBsAg seroconversion2
ALT normalization3
SecondaryNumber of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)

All participants who received at least one dose of the study drug were analysed. Number of participants with any adverse events and any serious adverse events are reported.

Time frame:
Up to Week 96
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)
ParticipantsPeginterferon Alfa-2a
Any AEs3
Any SAEs0
SecondaryMean Change in Laboratory Parameters (ALT Levels)

Mean Change in Laboratory parameters (ALT levels) is reported.

Time frame:
From Screening (Day 0) to Week 96
Reported as:
Mean · International units per liter (IU/L)
Mean Change in Laboratory Parameters (ALT Levels)
International units per liter (IU/L)Peginterferon Alfa-2a
ALT (Week 1)92.9 ± 73.2
ALT (Week 2)97.2 ± 89.9
ALT (Week 4)109.4 ± 133.6
ALT (Week 8)81.2 ± 105.4
ALT Week 12)65.1 ± 35.9
ALT (Week 18)53.3 ± 26.2
ALT (Week 24)66.2 ± 32.3
ALT (Week 32)55 ± 30.2
ALT (Week 40)46 ± 17.6
ALT (Week 48)38.4 ± 18.4
ALT (Week 52)37.1 ± 5.1
ALT (Week 60)40.5 ± 15.1
ALT (Week 72)36.9 ± 4.5
ALT (Week 96)32.8 ± 8.1

Adverse events

Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alfa-2a—0/18 (0%)3/18 (16.7%)
Most frequent other events
Most frequent other events
EventPeginterferon Alfa-2a
NeutropeniaBlood and lymphatic system disorders2/18
DepressionPsychiatric disorders1/18

Baseline characteristics

All participants who received at least one dose of the study drug were included.

Age, Categorical
Age, Categorical(Participants)Peginterferon Alfa-2a
<=18 years0
Between 18 and 65 years18
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alfa-2a
Female4
Male14
Hepatitis B Early Antigen (HBeAg) positive participants
Hepatitis B Early Antigen (HBeAg) positive participants(participants)Peginterferon Alfa-2a
Number4
HBeAg-negative participants
HBeAg-negative participants(Participants)Peginterferon Alfa-2a
Count of participants14
08

Study locations

23 sites
  • Chelyabinsk, 454052, Russian Federation
  • Ekaterinburg, 620020, Russian Federation
  • Ekaterinburg, 620102, Russian Federation
  • Irkutsk, 664047, Russian Federation
  • Kazan, 420097, Russian Federation
  • Krasnoyarsk, 660049, Russian Federation
  • Moscow, 111020, Russian Federation
  • Moscow, 115516, Russian Federation
  • Moscow, 121293, Russian Federation
  • Moscow, 123367, Russian Federation
  • Moscow, Russian Federation
  • Nizhny Novgorod, 603022, Russian Federation
  • Novokuznetsk, 654063, Russian Federation
  • Novosibirsk, 630016, Russian Federation
  • Rostov-na-donu, 344010, Russian Federation
  • Samara, 443021, Russian Federation
  • St Petersburg, 190103, Russian Federation
  • Stavropol, 355017, Russian Federation
  • Tomsk, 634050, Russian Federation
  • Tumen, 625002, Russian Federation
  • UFA, 450000, Russian Federation
  • Volgograd, 400138, Russian Federation
  • Yakutsk, 677000, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 7 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2007
First posted
Jun 19, 2007
Start
Aug 2006
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Apr 6, 2017
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00487747
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 19, 2007
Start date
Aug 2006
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Apr 6, 2017
Last update
Apr 6, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion